

## ARTICLE OPEN



# p53-mediated redox control promotes liver regeneration and maintains liver function in response to CCl<sub>4</sub>

Timothy J. Humpton<sup>1,2</sup>, Holly Hall<sup>2</sup>, Christos Kiourtis<sup>2,3</sup>, Colin Nixon<sup>2</sup>, William Clark<sup>2</sup>, Ann Hedley<sup>2</sup>, Robin Shaw<sup>2</sup>, Thomas G. Bird<sup>2,4</sup>, Karen Blyth<sup>2,3</sup> and Karen H. Vousden<sup>1</sup>

© The Author(s) 2021

The p53 transcription factor coordinates wide-ranging responses to stress that contribute to its function as a tumour suppressor. The responses to p53 induction are complex and range from mediating the elimination of stressed or damaged cells to promoting survival and repair. These activities of p53 can modulate tumour development but may also play a role in pathological responses to stress such as tissue damage and repair. Using a p53 reporter mouse, we have previously detected strong induction of p53 activity in the liver of mice treated with the hepatotoxin carbon tetrachloride (CCl<sub>4</sub>). Here, we show that p53 functions to support repair and recovery from CCl<sub>4</sub>-mediated liver damage, control reactive oxygen species (ROS) and limit the development of hepatocellular carcinoma (HCC), in part through the activation of a detoxification cytochrome P450, CYP2A5 (CYP2A6 in humans). Our work demonstrates an important role for p53-mediated redox control in facilitating the hepatic regenerative response after damage and identifies CYP2A5/CYP2A6 as a mediator of this pathway with potential prognostic utility in human HCC.

*Cell Death & Differentiation* (2022) 29:514–526; <https://doi.org/10.1038/s41418-021-00871-3>

## INTRODUCTION

The TP53 (p53) transcription factor coordinates diverse aspects of the cellular stress response and is capable of engaging both pro-survival and pro-death pathways [1]. Although p53 was initially identified through its association with cancer, it also has broader roles in organismal health. p53 is required for efficient implantation of embryos into the uterus [2], promotes stamina during exercise [3, 4], limits fibrosis after chronic liver injury [5], and protects against *Listeria monocytogenes* infection [6]. Conversely, unrestrained activation of p53 in embryos is rapidly lethal [7–9], p53 promotes B-cell apoptosis in type 2 diabetes mellitus [10], and in ischaemia, inhibition of p53 is protective [11–13]. These disparate outcomes suggest a nuanced balance between divergent aspects of p53 activity.

The liver provides an excellent setting in which to examine the intersection of p53 signalling in cancer and normal biology. Disruption of *TP53* is observed in 30–40% of human hepatocellular carcinomas (HCCs) [14], suggesting tumour-suppressive functions for p53 in the liver. Indeed, the loss of hepatic p53 alone is sufficient to promote liver cancer in mice, albeit at long latency [15]. Even so, wild-type p53 is retained in more than half of human HCCs, with a previously identified *TP53* gene expression signature characterising this group [14]. These observations suggest that aspects of p53 function may also support—or at least not directly antagonise—hepatic tumourigenesis.

Although the liver is largely quiescent in adults, it can undergo rapid regeneration after damage or resection [16]. As

in HCC, the p53 pathway has been reported to support and antagonise liver regeneration. It has been shown that p53 limits liver damage after acetaminophen overdose and protects mitotic fidelity after partial hepatectomy, indicating protective roles for p53 in the hepatic injury response [17–19]. Similarly, p53-deficient mice exhibit enhanced sensitivity to high-dose irradiation during CCl<sub>4</sub>-induced regeneration [20]. In addition, the loss of CDKN1A/p21, a p53 target, has been reported to impair liver regeneration in certain liver damage models [21, 22]. However, robust activation of p21 has also been shown to promote senescence and to limit the regenerative response, and p21 loss can allow for survival after severe liver damage—suggesting that this arm of the p53 response may also impede liver regeneration [21, 23]. More directly, unrestrained activation of p53 is lethal in hepatocytes, p53-mediated apoptosis contributes to disease progression in a model of non-alcoholic steatohepatitis, and p53 activity promotes fibrosis in a model of chronic regeneration in rats [24–27]. Thus, the role of p53 in the hepatic response to toxic damage is not clear and may be dependent on the nature and severity of the initiating damage.

Here, we utilise CCl<sub>4</sub>-mediated liver regeneration as a model system to investigate the function of p53 in liver biology. Our work demonstrates a role for p53-mediated redox control in facilitating the hepatic regenerative response after damage. We identified CYP2A5/CYP2A6 as a mediator of this pathway with potential prognostic utility in human HCC.

<sup>1</sup>The Francis Crick Institute, London NW1 1AT, UK. <sup>2</sup>Cancer Research UK Beatson Institute, Glasgow G61 1BD, UK. <sup>3</sup>Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK. <sup>4</sup>MRC Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, UK. ✉email: tim.humpton@crick.ac.uk; karen.vousden@crick.ac.uk  
Edited by G. Melino

Received: 27 November 2020 Revised: 26 August 2021 Accepted: 7 September 2021  
Published online: 9 October 2021

## RESULTS

### Liver-specific loss of p53 exacerbates liver damage and increases ROS during CCl<sub>4</sub>-mediated liver regeneration

Using a p53 reporter mouse, we have previously detected strong induction of the p53 pathway, albeit without clear accumulation of p53 itself, in hepatocytes of mice treated with the hepatotoxin carbon tetrachloride (CCl<sub>4</sub>). To explore the potential roles for p53 function during this process, we created mice harbouring liver-specific deletion of *Trp53* (*p53*) (*Albumin-Cre; p53<sup>FL/FL</sup>* mice), confirmed that recombination of the *p53* floxed allele was highly efficient in the liver (Fig. S1A/B) and proceeded to characterise the acute response to CCl<sub>4</sub>-mediated liver toxicity using this model (Figs. 1A/B and S1 C–H). Importantly, mice of either *p53* genotype developed normally and were histologically indistinguishable prior to treatment (Fig. S1 C/D). Within the first 24 h following treatment with CCl<sub>4</sub>, *Albumin-Cre; p53<sup>WT/WT</sup>* mice (*p53* WT) mice exhibited evident liver damage, including vacuolisation, neutrophil infiltration, and destruction of Glutamine Synthetase (GS)-positive peri-central vein hepatocytes (Figs. 1A/B and S1C–H). Damage progressed outward from the central vein over the first 48–72 hours after treatment before resolving within the remainder of the 168-h time-course (Figs. 1A/B and S1 C/D). In *Albumin-Cre; p53<sup>FL/FL</sup>* mice, although GS-positive hepatocyte destruction and damage-associated neutrophil infiltration were similar to *p53* WT mice (Fig. S1E–H), liver damage progressed outward from the peri-central vein region more rapidly, coalescing into larger regions of injury at 24 h after CCl<sub>4</sub> treatment (Figs. 1A/B and S1 C/D). Even so, the liver damage in *Albumin-Cre; p53<sup>FL/FL</sup>* mice also resolved within 168 h.

To confirm our histological assessment of liver damage, we examined the presence of alanine and aspartate transaminase (ALT/AST) activity in blood plasma, two markers of liver damage. In agreement with the liver histology, we noted extended elevation of plasma ALT and AST activity in *Albumin-Cre; p53<sup>FL/FL</sup>* mice (Fig. 1C/D), suggesting elevated liver damage in these mice. Even so, as observed in liver histology, plasma ALT and AST levels ultimately normalised by 168 h after treatment in mice of both genotypes, suggesting potentially significant but transient effects of p53 during CCl<sub>4</sub>-mediated liver regeneration. These findings are consistent with previous reports of p53 acting to limit liver damage after acetaminophen overdose [18, 19], where p53 exerted short-lived protective effects.

One of the features of damage-mediated liver regeneration is the dramatic but transient microvesicular steatosis that occurs prior to initiation of the proliferative phase of the regenerative response [28–30]. The resulting accumulation of lipids can be visualised as red puncta in oil-red O-stained liver sections. In contrast to our liver damage assessments, we observed a similar peak accumulation of oil-red-O staining at 24 h after CCl<sub>4</sub> treatment in the livers of *Albumin-Cre; p53<sup>WT/WT</sup>* and *Albumin-Cre; p53<sup>FL/FL</sup>* mice (Fig. 1E/F). However, while lipid levels rapidly normalised by 48 h after treatment in *Albumin-Cre; p53<sup>WT/WT</sup>* mice, elevated oil-red-O staining persisted in *Albumin-Cre; p53<sup>FL/FL</sup>* mice for an additional 2 days (Fig. 1E/F).

The initial reductive dehalogenation of CCl<sub>4</sub> generates short-lived but highly reactive intermediates that potentially oxidise lipids and cause DNA damage [31, 32]. Peroxidized lipids can impede mitochondrial function, including fatty acid oxidation, and impair lipid export—potentially contributing to lipid accumulation during CCl<sub>4</sub> detoxification [33–35]. Considering the established role for p53 supporting the redox response [36], we investigated whether the disrupted lipid clearance in *Albumin-Cre; p53<sup>FL/FL</sup>* mice was a consequence of decreased ROS detoxification. Indeed, levels of malondialdehyde (MDA), a marker of lipid peroxidation, were elevated to a greater extent, and for an additional two days, in *Albumin-Cre; p53<sup>FL/FL</sup>* mice compared with *Albumin-Cre; p53<sup>WT/WT</sup>* mice (Fig. 1G/H).

To investigate the contribution of ROS stress to deficiencies in liver regeneration in *Albumin-Cre; p53<sup>FL/FL</sup>* mice, we compared CCl<sub>4</sub>-mediated regeneration between *Albumin-Cre; p53<sup>FL/FL</sup>* mice given normal drinking water to those provided with N-Acetylcysteine (NAC)-supplemented drinking water. NAC treatment is an established antidote to liver toxicity that results from acetaminophen overdose in humans and functions by maintaining liver glutathione levels during the detoxification process [37]. As expected, NAC treatment significantly attenuated lipid peroxidation in *Albumin-Cre; p53<sup>FL/FL</sup>* mice (Fig. 1I/J). NAC treatment also promoted significantly more rapid clearance of lipid droplets (Fig. 1K/L), suggesting that redox management is an important feature of the p53-mediated response to hepatic CCl<sub>4</sub> toxicity.


### Liver p53 engages *Cyp2a5/CYP2A6* to support redox control during CCl<sub>4</sub>-mediated liver regeneration

Given the differences in redox control between *Albumin-Cre; p53<sup>WT/WT</sup>* and *Albumin-Cre; p53<sup>FL/FL</sup>* mice at 24 h after CCl<sub>4</sub> treatment, we focused on the early response to toxicity. At 8 h after CCl<sub>4</sub> treatment, we observed similar oil-red-O staining to baseline and comparable lipid peroxidation between livers taken from *Albumin-Cre; p53<sup>WT/WT</sup>* and *Albumin-Cre; p53<sup>FL/FL</sup>* mice (Fig. 2A/B), suggesting that bifurcation of the regenerative response had not yet occurred. Bulk RNA-seq analysis at this time point identified 13 significant differentially regulated genes between *Albumin-Cre; p53<sup>WT/WT</sup>* and *Albumin-Cre; p53<sup>FL/FL</sup>* livers 8 h after CCl<sub>4</sub> treatment (Fig. S2A). Clustering analysis stratified these genes into three groups, one of which contained p53 itself and four established p53 targets: *Ccng1/Cyclin G1*, *Eda2r*, *Zmat3/Wig-1*, and *Abcb1a/Mdr1* [38–41] (Fig. 2C). Our attention was drawn to the remaining member of this cluster, *Cyp2a5*, encoding a cytochrome P450 enzyme that is induced by NFE2L2 (NRF2) to aid in the murine redox response during ethanol detoxification [42, 43]. *CYP2A6*, the human orthologue of *Cyp2a5* [44], has been shown to be a transcriptional target of p53 [45], suggesting potential p53-directed functions for *Cyp2a5* in the mouse as well.

Consistent with our RNA-seq data, we confirmed that expression of *Cyp2a5* was induced in *Albumin-Cre; p53<sup>WT/WT</sup>* mice within the first 8–24 h after CCl<sub>4</sub> treatment, with later induction observed in *Albumin-Cre; p53<sup>FL/FL</sup>* mice alongside increased levels of the NRF2 target gene *Nqo1* (Fig. S2B/C). Through IHC staining, we confirmed higher levels of CYP2A5 protein in livers of *Albumin-Cre; p53<sup>WT/WT</sup>* compared to *Albumin-Cre; p53<sup>FL/FL</sup>* mice within 24 h after CCl<sub>4</sub> treatment as well (Fig. 2D/E). CYP2A5 levels remained significantly elevated in *Albumin-Cre; p53<sup>WT/WT</sup>* livers at 48 and 72 h after treatment, with a delayed increase evident in *Albumin-Cre; p53<sup>FL/FL</sup>* livers at 48–72 h after CCl<sub>4</sub> treatment (Fig. 2D/E).

Interestingly, although we observed potent early induction of the p53 target gene *Cdkn1a/p21* in *Albumin-Cre; p53<sup>WT/WT</sup>* mice, this was matched by similar induction in *Albumin-Cre; p53<sup>FL/FL</sup>* mice, a finding that we confirmed by IHC staining for p21 at 8 h after CCl<sub>4</sub> treatment (Fig. S2D/E). These findings suggest that early expression of p21 after CCl<sub>4</sub> treatment is p53-independent (Fig. S2D/E), in contrast to its p53-dependent induction later in the regenerative process (Fig. S2D). These results also explain why *Cdkn1a* was not differentially expressed in our RNA-seq analysis. Expression of CYP2A5, in contrast, was elevated in *Albumin-Cre; p53<sup>WT/WT</sup>* mice but significantly lower in *Albumin-Cre; p53<sup>FL/FL</sup>* livers at this time point, consistent with our RNA-seq data (Fig. S2F). *Bbc3/Puma*, a pro-apoptotic p53 target gene that has been shown to play a role in modulating liver metabolism in human HCC [46], was not differentially expressed between *Albumin-Cre; p53<sup>WT/WT</sup>* and *Albumin-Cre; p53<sup>FL/FL</sup>* mice during CCl<sub>4</sub>-mediated regeneration (Fig. S2G), reinforcing the idea that not all aspects of p53 activity are engaged during liver regeneration.

In the *Mdm2<sup>Ex5/6Δ</sup>* mouse model, excision of *Mdm2* exons 5 and 6 (*Mdm2<sup>Ex5/6Δ</sup>*), comprising the p53-binding domain of MDM2,



leads to rapid stabilisation of p53, robust expression of p53 target genes, and ultimately in p53-dependent lethality within 4–5 days [24, 47]. RNA-seq analysis of mice sampled at two days after treatment with liver-specific AAV8-TBG-Cre [48] to induce expression of *Mdm2*<sup>EX5/6Δ</sup>, a time point before widespread liver attrition, confirmed significant induction of *Cyp2a5*. Indeed, we identified

all of the genes in our CCl<sub>4</sub> RNA-seq analysis, alongside classical p53 targets such as *p21* and *Puma* in this alternative model (Fig. S2H). As in the CCl<sub>4</sub> liver regeneration model, we validated the induction of *p21* and *CYP2A5*, as well as stabilisation of p53, via IHC (Fig. S2I–K). Combined, these findings confirm that activation of p53 engages CYP2A5 in the liver.

**Fig. 1 Loss of liver p53 exacerbates liver damage and increases ROS during CCl<sub>4</sub>-mediated liver regeneration.** Representative H&E images (A) and quantification (B) of damaged area (% per field) in livers from *Albumin-Cre; p53<sup>WT/WT</sup>* mice (WT) and *Albumin-Cre; p53<sup>FL/FL</sup>* (FL) mice at indicated times (hours) following CCl<sub>4</sub> treatment. Damaged areas outlined. Scale bars 100 μm. Higher magnification inset images highlight centrilobular liver damage including vacuolisation (black arrows). These images are taken from different H&E slides than those depicted for damaged area. Scale bars 10 μm. Images reproduced without annotation and at full size in Fig. S1 C/D. Quantifications from *N* = 2 untreated (0 h) mice/group, *N* = 6 mice/group at 24 h, *N* = 5 WT and *N* = 4 FL mice at 48 h, *N* = 7 mice/group at 72 h, *N* = 3 mice/group at 168 h. Data presented as mean ± SEM and analysed using two-way ANOVA with Holm-Sidak's multiple comparisons test and multiplicity-adjusted *p* values. \*\*\*\**p* < 0.0001. Plasma ALT (C) and AST (D) activity (mU/mL) in *Albumin-Cre; p53<sup>WT/WT</sup>* (WT) and *Albumin-Cre; p53<sup>FL/FL</sup>* (FL) mice treated as in (A). *N* = 3 untreated (0 h) mice/group. *N* = 4 mice/group/time point thereafter. Each data point represents the mean from technical duplicates per mouse. Data presented as mean ± SEM and analysed using two-way ANOVA with Holm-Sidak's multiple comparisons test and multiplicity-adjusted *p* values. \**p* < 0.05, \*\**p* < 0.01, \*\*\*\**p* < 0.0001. Staining (E) and quantification of stain area (F) of frozen sections for oil-red-O (ORO) in *Albumin-Cre; p53<sup>WT/WT</sup>* (WT) and *Albumin-Cre; p53<sup>FL/FL</sup>* (FL) mice treated as in (A). Scale bars 20 μm. Quantification from *N* = 5 untreated (0 h), 24 h, and 48 h mice/group, *N* = 7 mice/group at 72 h, and *N* = 3 mice/group at 168 h. Data presented as mean ± SEM and analysed using two-way ANOVA with Holm-Sidak's multiple comparisons test and multiplicity-adjusted *p* values. \**p* < 0.05, \*\*\**p* < 0.001. Data from *p53<sup>FL/FL</sup>* mice also used in (L) (normal water) but different representative images are shown. IHC staining (G) and quantification (H) of malondialdehyde (MDA) in *Albumin-Cre; p53<sup>WT/WT</sup>* (WT) and *Albumin-Cre; p53<sup>FL/FL</sup>* (FL) mice at indicated times (hours) after CCl<sub>4</sub> treatment. Scale bars 20 μm. Quantification from *N* = 6 untreated (0 h) mice/group, *N* = 7 WT and *N* = 6 FL mice at 24 h, *N* = 7 mice/group at 48 and 72 h, and *N* = 3 mice/group at 168 h. Data presented as mean ± SEM and analysed using two-way ANOVA with Holm-Sidak's multiple comparisons test and multiplicity-adjusted *p* values. \*\**p* < 0.01, \*\*\*\**p* < 0.0001. Data from *p53<sup>FL/FL</sup>* mice also used in (J) (normal water) but different representative images are shown. IHC staining (I) and quantification (J) of malondialdehyde (MDA) in *Albumin-Cre; p53<sup>FL/FL</sup>* (FL) mice given control (water) or 30 mM N-Acetylcysteine-supplemented drinking water (NAC) for one week prior to CCl<sub>4</sub> treatment. Images from indicated times (hours) after CCl<sub>4</sub> treatment. Scale bars 20 μm. Quantification from *N* = 6 water and *N* = 2 NAC untreated mice (0 h), *N* = 6 water and *N* = 4 NAC mice at 24 h, *N* = 7 water and *N* = 4 NAC mice at 48–72 h. Data presented as mean ± SEM and analysed using two-way ANOVA with Holm-Sidak's multiple comparisons test and multiplicity-adjusted *p* values. \*\**p* < 0.01, \*\*\*\**p* < 0.0001. Data from *p53<sup>FL/FL</sup>* (normal water) mice also used in (H) but different representative images are shown. Staining (K) and quantification (L) of oil-red-O (ORO) in *Albumin-Cre; p53<sup>FL/FL</sup>* (FL) mice given control (water) or 30 mM N-Acetylcysteine-supplemented drinking water (NAC) for one week prior to CCl<sub>4</sub> treatment. Images from indicated times (hours) after CCl<sub>4</sub> treatment. Scale bars 20 μm. Quantification from *N* = 5 untreated water (0 h) and *N* = 2 untreated NAC mice, *N* = 5 water and *N* = 4 NAC mice at 24 and 48 h, *N* = 7 water and *N* = 4 NAC mice at 72 h. Data presented as mean ± SEM and analysed using two-way ANOVA with Holm-Sidak's multiple comparisons test and multiplicity-adjusted *p* values. \**p* < 0.05. Data from *p53<sup>FL/FL</sup>* (normal water) mice also used in (F) but different representative images are shown.

To explore the role of CYP2A5/CYP2A6 in damaged hepatocytes more fully in vitro, we turned to HepG2 and SK-Hep-1 cells, human HCC cell lines that maintain wild type p53 [46] (Fig. 2F/G). Treatment of these cells with Nutlin, a direct activator of p53 [49], induced expression of *CDKN1A/p21*, as expected, as well as CYP2A6. Treatment of both HepG2 and SK-Hep-1 cells with CCl<sub>4</sub> also induced *p21* and CYP2A6 expression (Fig. 2F/G). This response was abrogated following siRNA-mediated depletion of TP53, confirming the role of p53 in the upregulation of *p21* and CYP2A6 expression in response to CCl<sub>4</sub> in vitro (Fig. 2F/G).

Functionally, both HepG2 and SK-Hep-1 cells treated with CCl<sub>4</sub> exhibited increased ROS levels, and this was exacerbated in CYP2A6-depleted cells (Fig. 2H/I). Treatment of HepG2 and SK-Hep-1 cells with cumene hydroperoxide (CH), a stable organic oxidising agent [50], similarly engaged CYP2A6 and *CDKN1A/p21* (Fig. S2 L/M), and CYP2A6-depletion also increased cellular ROS levels after CH treatment (Fig. 2J/K)—suggesting that downstream ROS, rather than CCl<sub>4</sub> directly, promotes activation of CYP2A6 to aid in ROS detoxification. Interestingly, although induction of CYP2A6 was p53-dependent in response to CCl<sub>4</sub> treatment, CYP2A6 increased independently of p53 after CH treatment (Fig. S2L/M). Since hydroperoxides have been shown to activate NRF2 in HepG2 cells [51], this finding is consistent with an established role for NRF2-induced *Cyp2a5* supporting the redox response during ethanol detoxification in mice [42, 43]. Based on these findings, we concluded that the p53-dependent activation of CYP2A5 in response to CCl<sub>4</sub> treatment in vivo contributed to the enhanced detoxification of lipid ROS in support of rapid regeneration in *Albumin-Cre; p53<sup>WT/WT</sup>* mice.


### Hepatocyte p53 protects liver function and limits tumorigenesis following CCl<sub>4</sub>-mediated chronic regeneration

A close relationship has been described between chronic regeneration and cancer—with tumorigenesis sometimes conceptualised as 'a wound that does not heal' [52]. While we detected clear defects in redox control and liver function during one round of CCl<sub>4</sub> treatment and regeneration in *Albumin-Cre; p53<sup>FL/FL</sup>* mice compared to *Albumin-Cre; p53<sup>WT/WT</sup>* mice, these


differences were transient and resolved within one week (Fig. 1). In contrast to acute damage, repeated regeneration resulting from regular CCl<sub>4</sub> treatment causes lasting fibrotic liver damage, leading to cirrhosis and HCC [53, 54]. This progression is exacerbated by systemic DNA damage, chronic inflammation, and ROS stress [55, 56]. With these findings in mind, we investigated the effects of lack of liver p53 on fibrosis and HCC development in the well-established CCl<sub>4</sub> chronic liver regeneration model [5] (Fig. S3A).

One week after the conclusion of the 10-week chronic regeneration regime, we observed striking generalised hepatocyte hypertrophy [57] throughout the livers of *Albumin-Cre; p53<sup>FL/FL</sup>* mice that was absent in similarly treated *Albumin-Cre; p53<sup>WT/WT</sup>* mice (Fig. 3A/B). In hepatic stellate cells (HSCs), p53 has been shown to limit fibrosis after chronic regeneration in the liver [5]. However, we found that hepatocyte-specific p53 loss did not lead to differences in activated HSC content, as evaluated by IHC staining for alpha-smooth muscle actin (αSMA), or to increased fibrosis as assessed by picrosirius red staining (PSR) (Fig. 3B–D). In fact, we observed a modest decrease in fibrosis in *Albumin-Cre; p53<sup>FL/FL</sup>* mice (Fig. 3B/D), consistent with a previous report showing that hepatocyte p53 can enhance fibrosis during CCl<sub>4</sub>-mediated chronic regeneration in rats [27]. Although murine hepatocyte p53 does not appear to limit fibrosis after chronic regeneration either, we nevertheless detected higher levels of unresolved DNA damage, measured by IHC staining for phosphohistone H2A.X (γH2AX), increased lipid peroxidation (measured by MDA) and—as expected—decreased levels of CYP2A5 in livers from *Albumin-Cre; p53<sup>FL/FL</sup>* mice (Fig. 3E/F). Functionally, we also found that plasma levels of ALT and AST enzyme activity were both elevated in *Albumin-Cre; p53<sup>FL/FL</sup>* mice after chronic regeneration, consistent with compromised liver function in these mice (Fig. 3G).

In wild-type mice, it can take up to 2 years for HCC to arise from chronic CCl<sub>4</sub> treatment [58]. Consistent with this, few *Albumin-Cre; p53<sup>WT/WT</sup>* mice (3/14) reached clinical endpoint within 550 days after initial CCl<sub>4</sub> treatment in our experimental cohorts (Fig. 4A). In contrast, *Albumin-Cre; p53<sup>FL/FL</sup>* mice exhibited accelerated and highly penetrant development of liver tumours in this timeframe



**Fig. 2 Liver p53 engages *Cyp2a5/CYP2A6* to support redox control during  $\text{CCl}_4$ -mediated liver regeneration.** Staining (A) and quantification (B) for malondialdehyde (MDA) and oil-red-O (ORO) in *Albumin-Cre; p53<sup>WT/WT</sup>* (WT) and *Albumin-Cre; p53<sup>FL/FL</sup>* (FL) mice at 8 h after  $\text{CCl}_4$  treatment. Scale bars 10  $\mu\text{m}$ . Representative of  $N = 3$  WT and  $N = 4$  FL mice. Data presented as mean  $\pm$  SEM and analysed using two-tailed t-tests and the Sidak–Bonferroni method to account for multiplicity of tests. ns not significant. **C** Clustering analysis of significant differentially expressed genes (adjusted  $p < 0.05$ ) from RNA-seq analysis between *Albumin-Cre; p53<sup>WT/WT</sup>* (WT) and *Albumin-Cre; p53<sup>FL/FL</sup>* (FL) mice at 8 h after  $\text{CCl}_4$  treatment. Samples from  $N = 3$  WT and  $N = 4$  FL mice included in analysis. Positive Z-score values correspond to genes enriched in livers of mice of the genotype indicated in the sample name. *Cyp2a5*-associated cluster as indicated. For further information, see materials and methods. IHC staining (D) and quantification (E) of CYP2A5 in *Albumin-Cre; p53<sup>WT/WT</sup>* (WT) and *Albumin-Cre; p53<sup>FL/FL</sup>* (FL) mice at indicated times (hours) after  $\text{CCl}_4$  treatment. Scale bars 20  $\mu\text{m}$ . Quantification from  $N = 4$  untreated (0 h) mice/group,  $N = 5$  mice/group at 24 h,  $N = 7$  mice/group at 48 and 72 h, and  $N = 3$  mice/group at 168 h. Data presented as mean  $\pm$  SEM and analysed using two-way ANOVA with Holm–Sidak’s multiple comparisons test and multiplicity-adjusted  $p$  values.  $***p < 0.001$ ,  $****p < 0.0001$ . RT-qPCR analysis of expression of *TP53*, *CDKN1A* and *CYP2A6* relative to *ACTIN* in HepG2 (F) and SK-Hep-1 (G) cells treated with siRNA against *TP53*, *CYP2A6* (2A6), or non-targeting control (NT) 96 h prior to analysis and additionally treated with either DMSO control (UT),  $\text{CCl}_4$  (4 mM), or with Nutlin (10  $\mu\text{M}$ ) for 24 h prior to analysis.  $N = 3$  independent samples/condition. Data presented as mean  $\pm$  SEM and analysed using two-way ANOVA with Holm–Sidak’s multiple comparisons test and multiplicity-adjusted  $p$  values.  $*p < 0.05$ ,  $**p < 0.01$ ,  $***p < 0.001$ ,  $****p < 0.0001$ . Measurement of cellular ROS levels relative to baseline using the CellROX fluorescent probe in HepG2 (H) and SK-Hep-1 (I) cells treated with non-targeting control (NT) or *CYP2A6* (2A6) siRNA for 96 hours and additionally treated with either DMSO control (UT) or with  $\text{CCl}_4$  (4 mM) in DMSO for 24 h prior to analysis.  $N = 5$  independent HepG2 and  $N = 3$  SK-Hep-1 samples/condition. Data presented as median fluorescent intensity (MFI)  $\pm$  SEM relative to untreated NT cells and analysed using two-way ANOVA with Holm–Sidak’s multiple comparisons test and multiplicity-adjusted  $p$  values.  $*p < 0.05$ ,  $**p < 0.01$ ,  $***p < 0.001$ ,  $****p < 0.0001$ . Measurement of cellular ROS levels relative to baseline using the CellROX fluorescent probe in HepG2 (J) or SK-Hep-1 cells (K) treated with non-targeting control (NT) or *CYP2A6* (2A6) siRNA for 96 h and additionally treated with either DMSO control (UT) or with cumene hydroperoxide (10  $\mu\text{M}$ ) (CH) for 24 h prior to analysis.  $N = 3$  independent samples/condition in HepG2 cells and  $N = 4$ /condition in SK-Hep-1 cells. Data presented as median fluorescent intensity (MFI)  $\pm$  SEM relative to untreated NT cells and analysed using two-way ANOVA with Holm–Sidak’s multiple comparisons test and multiplicity-adjusted  $p$  values.  $**p < 0.01$ ,  $***p < 0.001$ ,  $****p < 0.0001$ .



**Fig. 3** Loss of liver p53 leads to hepatic hypertrophy, chronic ROS and DNA damage, and impaired liver function after CCl<sub>4</sub>-mediated chronic regeneration. **A** Quantification of relative hepatocyte size in *Albumin-Cre; p53<sup>WT/WT</sup>* (WT) and *Albumin-Cre; p53<sup>FL/FL</sup>* (FL) mice at 7 days after completion of 10-week CCl<sub>4</sub> chronic regeneration regime.  $N = 9$  mice/genotype. Data presented as mean  $\pm$  SEM and analysed using an unpaired two-tailed  $t$ -test with Welch's correction.  $**p < 0.01$ . **B** H&E and IHC staining for alpha-smooth muscle actin (aSMA), and picosirius red (PSR) staining in *Albumin-Cre; p53<sup>WT/WT</sup>* (WT) and *Albumin-Cre; p53<sup>FL/FL</sup>* (FL) mice at 7 days after completion of 10-week CCl<sub>4</sub> chronic regeneration regime. Scale bars 10  $\mu$ m. Images representative of  $N = 10$  WT and  $N = 8$  FL mice for H&E,  $N = 4$  WT and  $N = 5$  FL mice for aSMA, and  $N = 7$  mice/group for PSR. **C** Quantification of IHC staining for aSMA in *Albumin-Cre; p53<sup>WT/WT</sup>* (WT) and *Albumin-Cre; p53<sup>FL/FL</sup>* (FL) mice from (B) at either 7 days after completion of 10-week CCl<sub>4</sub> chronic regeneration regime (chronic) or in untreated age-matched mice (control).  $N = 5$  control mice/genotype,  $N = 4$  WT and  $N = 5$  FL chronic mice. Data presented as mean  $\pm$  SEM and analysed using two-way ANOVA with Holm-Sidak's multiple comparisons test and multiplicity-adjusted  $p$  values.  $**p < 0.01$ . **D** Quantification of staining for picosirius red (PSR) in *Albumin-Cre; p53<sup>WT/WT</sup>* (WT) and *Albumin-Cre; p53<sup>FL/FL</sup>* (FL) mice as in (C).  $N = 4$  control mice/genotype and  $N = 7$  chronic CCl<sub>4</sub> mice/genotype. Data presented as mean  $\pm$  SEM and analysed using two-way ANOVA with Holm-Sidak's multiple comparisons test and multiplicity-adjusted  $p$  values.  $**p < 0.01$ ,  $***p < 0.001$ ,  $****p < 0.0001$ . Images (E) and quantification (F) of IHC staining MDA, CYP2A5, and gH2AX in *Albumin-Cre; p53<sup>WT/WT</sup>* (WT) and *Albumin-Cre; p53<sup>FL/FL</sup>* (FL) mice at 7 days after completion of 10-week CCl<sub>4</sub> chronic regeneration regime as in (C). Scale bars 20  $\mu$ m.  $N = 4$  mice/group for MDA,  $N = 7$  mice/group for CYP2A5, and  $N = 9$  mice/group for gH2AX. Data presented as mean  $\pm$  SEM and analysed using two-tailed  $t$ -tests and the Sidak-Bonferroni method to account for multiplicity of tests.  $**p < 0.01$ ,  $****p < 0.0001$ . **G** Plasma ALT and AST activity (mU/mL) in *Albumin-Cre; p53<sup>WT/WT</sup>* (WT) and *Albumin-Cre; p53<sup>FL/FL</sup>* (FL) mice at 7 days after completion of 10-week CCl<sub>4</sub> chronic regeneration regime.  $N = 7$  mice/group. Each data point represents the mean from technical duplicates per mouse. Data presented as mean  $\pm$  SEM and analysed using two-tailed  $t$ -tests and the Sidak-Bonferroni method to account for multiplicity of tests.  $***p < 0.001$ .


(9/9 mice, median survival 380 days after first CCl<sub>4</sub> treatment) (Fig. 4A). Most mice of both genotypes (2/3 *Albumin-Cre; p53<sup>WT/WT</sup>* mice and 5/9 *Albumin-Cre; p53<sup>FL/FL</sup>* mice) reaching clinical endpoint exhibited large tumour lesions but also retained non-tumour (normal-like) tissue (Fig. S3B). These regions were sampled as 'tumour' and 'non-tumour' tissue for subsequent analyses. At the experiment endpoint (550 days after initial treatment), most CCl<sub>4</sub>-treated *Albumin-Cre; p53<sup>WT/WT</sup>* mice (11/14), all untreated *Albumin-Cre; p53<sup>WT/WT</sup>* mice (10/10), and most untreated *Albumin-Cre; p53<sup>FL/FL</sup>* mice (13/14) remained alive.

Non-tumour liver tissue from *Albumin-Cre; p53<sup>FL/FL</sup>* mice retained the molecular features observed at the conclusion of the CCl<sub>4</sub> treatment regime, including prominent hypertrophy in remaining normal hepatocytes (Fig. 4B) and significantly reduced CYP2A5 expression (Fig. 4B, E). Analysis of tumours from *Albumin-Cre; p53<sup>WT/WT</sup>* mice (2 from mice at clinical endpoint and 2 small focal tumours identified at experiment endpoint) revealed that expression of CYP2A5 was elevated and MDA staining was low compared to tumours arising in *Albumin-Cre; p53<sup>FL/FL</sup>* mice (Fig. 4C–E and Fig. S3C). These results confirmed that the disparate features of regeneration in *Albumin-Cre; p53<sup>FL/FL</sup>* mice—namely elevated ROS, persistent liver damage, and decreased CYP2A5 expression—continued during tumourigenesis.

The p53-mediated expression of *BBC3/PUMA* has been shown to promote a pro-cancer metabolic switch in human HCC, correlating with poor prognosis in patients [46]. However, we did not observe differential expression of murine *Bbc3* in endpoint HCC tumours arising in *Albumin-Cre; p53<sup>WT/WT</sup>* mice after chronic CCl<sub>4</sub> treatment compared with those in *Albumin-Cre; p53<sup>FL/FL</sup>* mice (Fig. S3D). Expression of *Cdkn1a/p21*, in contrast, was elevated in the tumours of *Albumin-Cre; p53<sup>WT/WT</sup>* mice (Fig. S3D). These findings suggest that in murine HCC arising from chronic CCl<sub>4</sub> treatment the p53-PUMA mediated metabolic switch [46] is not a defining feature of p53 WT HCC.

#### CYP2A6 expression is prognostically favourable and clusters with a subset of p53-induced genes that correlate with increased survival in human HCC

Given the strength of the association between increased survival, retention of p53, and expression of CYP2A5 in the murine CCl<sub>4</sub> chronic regeneration model, we examined whether high expression of CYP2A6 correlated with increased survival in human HCC patients. Utilising the HCC dataset available through the cancer-genome atlas (TCGA-LIHC dataset [59]), we confirmed that high expression of CYP2A6 was associated with significantly greater median survival in HCC (Fig. 4F). In addition, by stratifying the



TCGA dataset between patients with disrupted *TP53* (mutation or loss) and those with WT *TP53*, we further determined that high expression of *CYP2A6* and retention of WT *TP53* coincided with increased survival compared with all other combinations of tumours harbouring low expression of *CYP2A6* and/or loss of WT *TP53* (Fig. 4G).

Previous work utilising TCGA data has focused on the genomic determinants of human HCC [14]. In these analyses, the authors' identified a 'p53-induced gene target expression signature' as part of an aim to improve the clustering of HCC based on molecular and biological attributes [14]. Using the TCGA-LIHC dataset, we examined the relationship between these 20 identified p53-induced genes and

**Fig. 4 Liver p53 controls ROS, maintains expression of CYP2A5, and limits tumourigenesis following CCl<sub>4</sub>-mediated chronic regeneration.** **A** Survival curve comparing *Albumin-Cre; p53<sup>WT/WT</sup>* (WT) and *Albumin-Cre; p53<sup>FL/FL</sup>* (FL) mice that were either untreated (UT) or administered the 10-week CCl<sub>4</sub> chronic regeneration regime and aged until either reaching clinical endpoint or 550 days after initiation of treatment. Data presented as time (days) since initial CCl<sub>4</sub> injection.  $N = 10$  WT and  $N = 14$  FL untreated mice,  $N = 14$  WT and  $N = 9$  FL chronic CCl<sub>4</sub>-treated mice. Of these, 0/10 WT and 1/14 FL UT mice and 3/14 WT and 9/9 FL CCl<sub>4</sub>-treated mice reached clinical endpoint within 550 days. All WT tumour mice (3/3) and the majority of FL endpoint tumour mice (5/9) exhibited focal tumour lesions along with substantial non-tumour (normal-like) tissue. These regions were sampled as 'tumour' and 'non-tumour' tissue for subsequent analyses. Within these cohorts,  $N = 4$  WT and  $N = 4$  FL untreated mice were examined at ~365 days and confirmed to be tumour free. Data analysed using Log-rank (Mantel–Cox) test. \*\*\*\* $p < 0.0001$ . **B** H&E and IHC staining for MDA and CYP2A5 in non-tumour liver tissue (**B**) and tumour tissue (**C**) from *Albumin-Cre; p53<sup>WT/WT</sup>* (WT) and *Albumin-Cre; p53<sup>FL/FL</sup>* ( $p53^{FL/FL}$ ) mice at clinical endpoint or 550 days post-treatment initiation after prior completion of 10-week CCl<sub>4</sub> chronic regeneration regime. Scale bars 20  $\mu$ m. Images representative of  $N = 5$  mice/group except  $N = 4$  WT tumours (2 from mice at clinical endpoint and 2 small focal tumours identified at experiment endpoint). Additional tumour images included in Supplemental Fig. 3B to illustrate staining from the diversity of tumours observed in the model. Quantification of IHC staining for MDA (**D**) and CYP2A5 (**E**) in *Albumin-Cre; p53<sup>WT/WT</sup>* (WT) and *Albumin-Cre; p53<sup>FL/FL</sup>* (FL) mice from (**B/C**). Data presented as mean  $\pm$  SEM and analysed using two-way ANOVA with Holm–Sidak's multiple comparisons test and multiplicity-adjusted  $p$  values. \* $p < 0.05$ , \*\* $p < 0.01$ . **F** Survival curve comparing HCC patients in the TCGA-LIHC dataset with high vs. low expression of *CYP2A6* (2A6) on the basis of median survival.  $N = 91$  *CYP2A6* high and  $N = 73$  *CYP2A6* low patients. Data analysed using the Log-rank (Mantel–Cox) test. \*\*\* $p < 0.001$ . **G** Survival curve comparing HCC patients in the TCGA-LIHC dataset on the basis of *TP53* status (loss or mutation of *p53* (mutant) vs. WT *TP53* (not mutant)) and further breakdown of high vs. low expression of *CYP2A6* (2A6) on the basis of median survival.  $N = 69$  2A6 high, not mutant,  $N = 22$  2A6 high, *TP53* mutant,  $N = 50$  2A6 low, not mutant, and  $N = 23$  2A6 low, *TP53* mutant. Data analysed using the Log-rank (Mantel–Cox) test. \*\*\* $p < 0.01$ , \*\*\*\* $p < 0.001$ . **H** Clustering analysis of expression of *CYP2A6* related to the previously identified 20 gene 'p53-Induced Gene Target Expression Signature' [14] using the TCGA-LIHC dataset. *CYP2A6*-associated cluster as indicated. For further information, see materials and methods. **I** Survival curve comparing HCC patients in the TCGA-LIHC dataset on the basis of high vs. low expression of the 'p53-Induced Gene Target Expression Signature' [14].  $N = 85/79$  patients in the high and low groups. This analysis is independent of patient *p53* status and includes all data in the TCGA-LIHC dataset. Data analysed using the Log-rank (Mantel–Cox) test. \*\*\* $p < 0.001$ . **J** Survival curve comparing HCC patients in the TCGA-LIHC on the basis of high vs. low expression of the subset of genes within the 'p53-Induced Gene Target Expression signature' that clustered with *CYP2A6* expression in (**H**).  $N = 91/73$  patients in the high and low groups. Data analysed using the Log-rank (Mantel–Cox) test. \* $p < 0.05$ .

*CYP2A6* expression and found that *CYP2A6* expression clustered with a subset of the p53-induced genes including *GADD45B*, *ALDH4A1*, *GADD45A*, *ESR1*, *PANK1*, and *ACAD11* (Fig. 4H). Interestingly, although high expression of the full p53-induced gene target expression signature correlated with significantly reduced median survival in the TCGA-LIHC dataset (Fig. 4I), we found that high expression of the *CYP2A6*-associated gene cluster instead correlated with improved median survival (Fig. 4J). Taken together, these observations are consistent with a role for p53 and *CYP2A6* in limiting liver cancer.

## DISCUSSION

Tissue regeneration recapitulates many features of tumourigenesis, including potent activation of proliferative signalling pathways, changes to cellular metabolism, and rapid cell growth [60]. With this overlap in mind, we have examined the function of the canonical tumour suppressor protein p53 during regeneration. Using the liver as a model system, we have interrogated non-tumour roles for p53 activity during both the acute and chronic responses to the liver toxin and carcinogen CCl<sub>4</sub>. We identified p53-mediated redox control and induction of *CYP2A5/CYP2A6* as important features of the hepatic p53 response both in vivo and in human liver cancer cell lines in vitro.

Our findings suggest that a p53 programme is active during the priming phase of acute CCl<sub>4</sub>-mediated regeneration that includes induction of *Cyp2a5*, a cytochrome P450 enzyme that can be induced to control ROS in the liver [42, 43, 61]. In *TP53* WT human HCC cell lines in vitro, we show that *CYP2A6*, the human orthologue to murine *Cyp2a5*, is similarly engaged in a p53-dependent manner in response to CCl<sub>4</sub> or Nutlin treatment, as well as in response to treatment with a ROS-inducing agent, cumene hydroperoxide. In treated cells, the loss of *CYP2A6* exacerbates redox stress, confirming the role of *CYP2A6* in supporting ROS control. Consistent with this observation, we show that p53 acts to limit the propagation of CCl<sub>4</sub>-mediated damage by controlling resulting ROS. These ROS-control activities, likely alongside additional functions of p53, promote rapid regeneration and restoration of normal liver function that is delayed in the absence of liver p53.

Our results are somewhat at odds with a previous report where *Cyp2a5* was not shown to play a significant role in the hepatic response to CCl<sub>4</sub> toxicity [62]. However, this study examined *CYP2A5* activity only at 24 h after administration of a significantly smaller dose of CCl<sub>4</sub> to initiate acute regeneration—leading to markedly less liver damage than observed in our model. This discrepancy raises the interesting possibility that p53 activation may require a threshold of liver damage, ROS, or other stimuli to be sufficiently engaged. Given that DNA damage occurs during CCl<sub>4</sub> toxicity, the severity of induced DNA damage may play a role, and future work examining this prospect could clarify the activating signals that direct p53 during liver regeneration.

During the repeated damage of CCl<sub>4</sub>-mediated chronic liver regeneration, we found that the paradigms identified in acute regeneration persist. The presence of hepatic p53 does not limit, but rather leads to a slight increase in fibrosis in our model. Nevertheless, as in acute regeneration, p53 continues to engage *CYP2A5*, restrict lipid peroxidation, and maintain liver architecture and function. These protective actions are blunted in livers that lack p53, leading to pervasive hepatocyte hypertrophy, chronically increased ROS, unresolved DNA damage, and ultimately to mortality from liver cancer. Thus, in our system, increased fibrosis is not required for increased tumourigenesis. Further work is warranted to more carefully examine the relationship between fibrosis, p53 signalling, and liver tumourigenesis.

Our findings generalise to human HCC, where high expression of *CYP2A6* correlates with increased median survival, as well as increased survival in the subset of patients that retain WT *TP53* and maintain high expression of *CYP2A6*. These results suggest that increased *CYP2A6* expression is an important component of p53's tumour-suppressive function. Even so, our results also suggest that elevated *CYP2A6* alone is not sufficient to substitute for p53 activity in limiting liver tumourigenesis, consistent with the diverse repertoire of p53 tumour-suppressive activities in the cell. We have further distinguished a group of six genes previously reported as part of a p53-induced gene signature in human HCC [14] whose expression clusters with *CYP2A6* and together account for improved median survival—in contrast with the poor prognosis associated with high expression of the entire gene set.



Focusing on this point, we were surprised that high expression of the whole p53 gene signature significantly reduced median patient survival. However, it has been shown that p53 can help to protect cancer cells from nutrient starvation [63, 64], reduce cell death from ferroptosis [65, 66], and enhance redox control to limit ROS [67, 68]. In addition, common tumour-derived p53 mutants have been found to retain aspects of WT p53 function that promote adaptation to metabolic stress [69, 70]. With these findings in mind, and considering that 'pro-tumourigenic' p53 is an established paradigm in skin carcinogenesis [71–73], it is conceivable that aspects of p53 function can also enhance tumourigenesis in the liver. Future work investigating this possibility is warranted.

In humans, expression of *CYP2A6* and of various *CYP2A6* polymorphisms have been linked to higher rates pancreatic and colorectal cancer but to mostly reduced rates of lung and oesophageal cancer [74–78]. These findings suggest tissue, and potentially carcinogen-specific, functions for *CYP2A6* in limiting or promoting tumourigenesis. In the liver, our findings suggest that expression of *CYP2A6* is beneficial. One method to infer *CYP2A6* activity non-invasively is through the analysis of *CYP2A6*-derived urinary metabolites of caffeine [74, 75]. Increased consumption of coffee reduces the risk of developing HCC [79]. As such, it would be interesting to examine whether caffeine consumption promotes *CYP2A6* expression. If so, this pathway could account for some of the protective features of coffee consumption against HCC. Future work examining this relationship, as well as whether *CYP2A6* activity in HCC patients has prognostic or stratification value, is warranted.

Taken together, our results underscore the importance of p53 for maintaining liver function following damage. Interestingly, in contrast to previous models showing that the tumour suppressor function of p53 is a reflection of its ability to drive the elimination of damaged cells [80], our work shows that the repair and survival activities of p53 can also suppress the development of HCC.

## MATERIALS AND METHODS

### Mice

Procedures involving mice were performed under Home Office licence numbers 70/8645, PP6345023, and 70/8891. Experiments were conducted in accordance with the Animals (Scientific Procedures) Act 1986 and the EU Directive 2010 and sanctioned by Local Ethical Review Process (University of Glasgow). Mice were housed on a 12-h light/12-h dark cycle and provided with normal chow diet and water *ad libitum*. Mice were genotyped by Transnetyx (Cordova, TN).

*p53<sup>FL/FL</sup>* (*Trp53<sup>tm1Bm</sup>*), *Albumin-Cre* (*Speer6-ps1<sup>Tg</sup>(Alb-cre)21Mgn*), and *Mdm2<sup>Ex5/6Δ</sup>* (*Mdm2<sup>tm2.1Glo</sup>*) mice were described previously [47, 81, 82].

For acute CCl<sub>4</sub>-mediated liver regeneration, mice were treated as previously described [53, 83]. In brief, young male *Albumin-Cre*; *p53<sup>WT/WT</sup>* and *Albumin-Cre*; *p53<sup>FL/FL</sup>* mice (approx. 70 days old) were given CCl<sub>4</sub> (1 mL/kg from stock solution of 20% CCl<sub>4</sub> v/v in corn oil) (Sigma cat# 289116 and C8267) via a single intraperitoneal (IP) injection administered in the morning. Mice receiving NAC-supplemented drinking water were provided with 30 mM NAC (Sigma cat# A7250) in water *ad libitum* for 72 h prior to treatment with CCl<sub>4</sub> and throughout the recovery period after treatment.

For chronic CCl<sub>4</sub>-mediated liver regeneration, young male *Albumin-Cre*; *p53<sup>WT/WT</sup>* and *Albumin-Cre*; *p53<sup>FL/FL</sup>* mice (approx. 70 days old) were treated weekly with IP injections of CCl<sub>4</sub> (1 mL/kg from stock solution of 20% CCl<sub>4</sub> v/v in corn oil) for 10 consecutive weeks. Separate cohorts of mice were either sampled 7 days after the final injection or monitored until reaching clinical endpoint (or 550 days after the first injection) and sampled at this time.

Cohorts were composed of fully backcrossed C57BL/6J (N10) *Albumin-Cre*; *p53<sup>WT/WT</sup>* and *Albumin-Cre*; *p53<sup>FL/FL</sup>* male mice. Some mice from both genotypes also contained the *Rosa26<sup>eLSL-tRFP</sup>* (*Gt(ROSA)26Sor<sup>tm1Hjf</sup>*) reporter allele [84], which did not affect the response to CCl<sub>4</sub> treatment. The experimental unit in all of our analyses was the individual mouse. No statistical test was performed to predetermine sample size. Initial pilot studies suggested a strong effect of liver p53 status on the response to CCl<sub>4</sub> treatment 24–72 h after administration, and subsequent experiments were performed using sample sizes based on standard protocols in the field. No animals were excluded from analysis. Within each experiment, mice were age and littermate

matched as much as possible, and all treated at the same time. Downstream analyses were performed on a random order of samples blinded to the genotype and treatment regime until the summation of results.

For *Mdm2<sup>Ex5/6Δ</sup>* RNA-seq experiments, mice homozygous for the *Mdm2<sup>tm2.1Glo</sup>* allele were bred on a mixed background. 8–12 week old male mice were injected with either AAV8.TBG.PI.Cre.rBG (Addgene, 107787-AAV8) or AAV8.TBG.PI.Null.bGH (Addgene, 105536-AAV8) at a dose of  $2 \times 10^{11}$  genetic copies/mouse, as described previously [23]. Male mice of the same age and genotype, but without AAV injection, served as baseline controls (Untreated/uninduced controls). All mice were euthanized at 48 h post-AAV injection via CO<sub>2</sub> inhalation.

### Recombination PCR

For recombination PCR, liver DNA from *Albumin-Cre*; *p53<sup>WT/WT</sup>* mice (WT) and liver and kidney DNA from *Albumin-Cre*; *p53<sup>FL/FL</sup>* (*p53<sup>FL/FL</sup>*) adult mice were isolated as previously described [85]. DNA was amplified using KOD Hot Start Master Mix (Merck Millipore cat# 71842) according to standard protocols. PCR primers were previously described [86].

### Liver function assays (ALT/AST)

ALT and AST activity were determined in EDTA-treated plasma using the Alanine Transaminase Activity Assay Kit (ab105134) and the Aspartate Aminotransferase Activity Assay Kit (ab138878) from Abcam. Both assays were performed following the manufacturer's recommendations. Samples were run together, analysed in duplicate wells per mouse sample, and the mean value of these technical replicates was used for subsequent analysis.

### Immunohistochemistry (IHC) and special staining

Staining for oil-red-O was performed on 10 μm frozen sections that were first fixed for 5 min in 10% neutral buffered formalin (Solmedia), rinsed in tap water, and then briefly rinsed in 60% isopropanol (Fisher Chemicals). Slides were stained in freshly prepared and filtered oil-red-O staining solution (0.5% w/v oil-red-o (Merck Life Science, UK) in isopropanol (Fisher Chemicals)) for 15 min with agitation. Slides were subsequently blotted, rinsed with 60% isopropanol and then water, before application of Mayers Haematoxylin (Sigma Aldrich) to stain the nuclei. Stained slides were first sealed using Aqueous mountant (Dako) and left overnight before being coverslipped using DPX mountant (CellPath, UK).

Staining for PSR was performed on 4 μm formalin-fixed paraffin-embedded sections that were de-waxed and rehydrated through xylene and a graded ethanol series. Rehydrated slides were stained for 2 h in PSR staining solution (equal volumes of 0.1% Direct red 80 (Sigma Aldrich) and 0.1% Fast green (Raymond A Lamb) (both in distilled water) combined in a 1:9 dilution with aqueous Picric acid solution (VWR)), rinsed in tap water, and dehydrated through a graded ethanol series and xylene before being coverslipped using DPX mountant (CellPath, UK).

Manual and automated IHC staining were performed as previously described [69, 85] with the reagents and staining platform used for each antibody as noted in the accompanying reagent and antibody information tables (Supplementary Tables 1 and 2).

### Analysis of IHC images

The analysis of IHC staining in CCl<sub>4</sub> experiments, and for *CYP2A5* IHC staining in *Mdm2<sup>Ex5/6Δ</sup>* mice, was performed as previously described [69, 85].

For the analysis of IHC staining for p53 and p21 in *Mdm2<sup>Ex5/6Δ</sup>* mice, a Leica Aperio AT2 slide scanner (Leica Microsystems, UK) was used to scan stained sections at 20× magnification. Histological scoring was performed using HALO image analysis software (V3.1.1076.363, Indica Labs).

### Quantification of liver damage

A minimum of five random non-overlapping 4× magnification fields were taken from each H&E stained slide using an Olympus BX51 microscope with Zen Blue software (Zeiss). From these images, damage was manually traced and the total damaged area per slide was calculated using imageJ software.

### Cell culture

HepG2 (HB-8065) and SK-Hep-1 (HTB-52) cells were obtained from ATCC but were not authenticated. Mycoplasma testing was performed when cells were thawed and semi-regularly thereafter using the MycoAlert Mycoplasma Detection Kit (Lonza LT07-318). Independent experiments were performed on cells treated with siRNA and compounds from separate

passages of each cell line. Stock flasks were maintained in DMEM glucose, glutamine, and phenol red-free medium (Gibco, A1443001) supplemented with 4 mM glucose (Sigma cat# 49163), 1 mM pyruvate (Gibco cat# 11360088), 1 mM L-Glutamine (Gibco cat# 25030032), penicillin/streptomycin (Gibco cat# 15070063), Gentamycin (Gibco cat# 15750037), and 10% FBS (Gibco cat# 10091148). Cells were cultured at 37 °C in a humidified atmosphere of 5% CO<sub>2</sub>.

Cells were treated with 10 μM Nutlin-3a (Nutlin) (Sigma cat# SML0580) dissolved in DMSO, 4 mM CCl<sub>4</sub> (Sigma cat# 289116) dissolved in DMSO, 10 μM cumene hydroperoxide (Thermo Fisher Scientific cat# C10445) dissolved in DMSO, or DMSO as vehicle control. For in vitro experiments, CCl<sub>4</sub> was prepared by first combining an 80/20 (v/v) mixture of CCl<sub>4</sub> and DMSO with media to make a 100× stock. The stock was then sonicated for 5 min to disperse the CCl<sub>4</sub> mixture and the resulting solution was added to cells.

### Transfection with siRNA

Studies utilising siRNA knockdown were performed as previously described [69], with siGENOME SMARTpool siRNA constructs (Horizon) used for the non-targeting siRNA control pool (D-001206-13-05) and to target *P53* (M-003329-03-0005) and *CYP2A6* (M-008781-02-0005). Constructs were used to transfect cell lines at 20 nM concentration using the Lullaby siRNA transfection reagent and the manufacturer's recommended reverse transfection procedure (OZ Biosciences).

### Flow cytometry

HepG2 and SK-Hep-1 cells were analysed for cellular ROS levels as previously described [69]. Data were analysed using FlowJo X 10.0.7r2 (FlowJo, LLC) and median fluorescence intensity values were obtained and compared across samples.

### RNA-seq

Liver samples were isolated and preserved in Allprotect tissue reagent (Qiagen cat# 76405) (CCl<sub>4</sub> samples) or snap frozen on dry ice and stored at -80 °C until RNA extraction (*Mdm2<sup>Ex5/6Δ</sup>* samples). To isolate RNA, tissue was homogenised using a Precellys tissue homogeniser (Bertin Instruments) and RNA was extracted using the RNeasy Plus Universal mini kit (Qiagen cat# 73404) (CCl<sub>4</sub> samples) or the RNeasy mini kit (Qiagen cat# 74104) (*Mdm2<sup>Ex5/6Δ</sup>* samples), all according to the manufacturers' recommendations. The quality of the purified RNA was tested on an Agilent 2200 TapeStation using RNA screentape (Agilent). Libraries for cluster generation and DNA sequencing were prepared as previously described using an Illumina TruSeq Stranded mRNA LT Kit (CCl<sub>4</sub> samples) or an Illumina TruSeq Stranded mRNA HT Kit (*Mdm2<sup>Ex5/6Δ</sup>* samples) [87]. The quality and quantity of the DNA libraries was assessed on an Agilent 2200 TapeStation (D1000 screentape) and Qubit (Thermo Fisher Scientific), respectively. The libraries were run on the Illumina Next Seq 500 using the High Output 75 cycles kit (2 × 36 cycles, paired-end reads, single index for CCl<sub>4</sub> samples and 2 × 36 cycles, paired-end reads, dual index for *Mdm2<sup>Ex5/6Δ</sup>* samples).

### Analyses of RNA-seq expression data

For CCl<sub>4</sub> RNA-seq, Fastq files were generated from the sequencer output using Illumina's bcl2fastq (version 2.15.0.4) and quality checks on the raw data were done using FastQC (version 0.10.1) [88] and FastQ Screen (version 0.4.2) [89]. Alignment of the RNA-Seq paired-end reads was to the GRCh38.75 [90] version of the mouse genome and annotation using Tophat (version 2.0.13) with Bowtie (version 2.2.6.0) [91]. Expression levels were determined and statistically analysed by a workflow combining HTSeq (version 2.2.4.0) [92], the R environment (version 3.4.2) [93], and packages from the Bioconductor data analysis suite [94]. Differential gene expression analysis was based on the negative binomial distribution using the DESeq2 package [95]. "Heatmap.2" function of gplots package [96] was used for hierarchical clustering of significant hits.

For *Mdm2<sup>Ex5/6Δ</sup>* RNA-seq, quality checks and trimming on the raw RNA-Seq data files were done using FastQC (version 0.11.7) [88], FastP [97] and FastQ Screen (version 0.12.0) [89]. RNA-Seq paired-end reads were aligned to the GRCh38.92 [90] version of the mouse genome and annotated using HISat2 version 2.1.0 [98]. Expression levels were determined and statistically analysed by a combination of HTSeq version 0.9.1 [92] and the R environment version 3.4 [93], utilising packages from the Bioconductor data analysis suite [94] and differential gene expression analysis based on

the negative binomial distribution using the DESeq2 package version 1.18.1 [95].

### TCGA analysis

Survival, mutation and expression data were obtained via cBioPortal [99, 100]. The results here are in whole or part based upon data generated by the TCGA Research Network (<http://cancergenome.nih.gov/>), using the TCGA-LIHC dataset [59].

The optimal cut-off point for high or low expression of *CYP2A6* in survival analyses was determined using the "surv\_cutpoint" function of survminer package in R (0.4.8) [93, 101]. Overall survival data from patients for each expression group was plotted and analysed using inbuilt tools as indicated in Prism 7 (Graph Pad). Correlations between *CYP2A6* expression and the 'P53-induced gene target expression signature' [14] were assessed using the "cor" function from base R [93]. Then, the resulting heatmap was plotted using the function "corrplot" from the corrplot package (Version 0.84) to plot heatmaps [102].

### Quantitative RT-PCR

For qPCR analysis of mouse tissue, liver samples were isolated and preserved in Allprotect tissue reagent (Qiagen cat# 76405). RNA was extracted as previously described [85]. cDNA was synthesised using the high capacity RNA-to-cDNA kit (Thermo Fisher Scientific cat# 4387406) and qPCR reactions were performed on a QuantStudio 5 real-time PCR system (Thermo Fisher Scientific) using Taqman FAST advanced master mix and Taqman gene expression assays (all Thermo Scientific) according to the manufacturer's recommendations and using the assays listed in Supplemental Table 3. Gene expression was quantified relative to the housekeeping gene *Beta-glucuronidase* according to the comparative ΔΔCt method.

For qPCR analysis of human cell lines, RNA was extracted from HepG2 and SK-Hep-1 cells using the RNeasy mini kit (Qiagen cat# 74104) according to the manufacturer's recommendations, omitting the optional additional DNase treatment step. cDNA synthesis and qPCR reactions were performed as for mouse tissue samples described above. Gene expression in human cell lines was quantified relative to the housekeeping gene *ACTIN* according to the comparative ΔΔCt method.

### Data plotting and statistical analysis

Data were plotted using Prism 7 (Graph Pad). The statistical analysis for each experiment was performed using the test indicated in the relevant figure legend and multiplicity-adjusted *p* values using the built-in analysis tools of Prism 7. Statistical tests were chosen based on the nature of the comparison being made and the corresponding standard tests utilised in the field. Underlying assumptions for these tests, including sample independence, variance equality, and normality were assumed to be met although not explicitly examined. Figures were prepared using Illustrator (Adobe). Unless otherwise indicated, data are represented as mean ± standard error of the mean (SEM) for error bars. Asterisks denote *p* value as follows: \**p* < 0.05, \*\**p* < 0.01, \*\*\**p* < 0.001, \*\*\*\**p* < 0.0001.

### DATA AVAILABILITY

The data that support the findings of this study are available from the corresponding authors upon reasonable request. RNA-seq data discussed in this paper have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession numbers GSE183053 and GSE183082.

### REFERENCES

- Levine AJ. p53: 800 million years of evolution and 40 years of discovery. *Nat Rev Cancer*. 2020;20:471–80. <http://www.nature.com/articles/s41568-020-0262-1>.
- Hu W, Feng Z, Teresky AK, Levine AJ. p53 regulates maternal reproduction through LIF. *Nature*. 2007;450:721–4. <http://www.nature.com/articles/nature05993>.
- Park J-Y, Wang P, Matsumoto T, Sung HJ, Ma W, Choi JW, et al. p53 Improves aerobic exercise capacity and augments skeletal muscle mitochondrial DNA content. *Circ Res*. 2009;105:705–12. <https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.109.205310>
- Matoba S, Kang J-G, Patino WD, Wragg A, Boehm M, Gavrillova O, et al. P53 regulates mitochondrial respiration. *Science*. 2006;312:1650–3. <http://www.ncbi.nlm.nih.gov/pubmed/16728594>.

5. Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, Miething C, et al. Senescence of activated stellate cells limits liver fibrosis. *Cell*. 2008;134:657–67. <https://linkinghub.elsevier.com/retrieve/pii/S0092867408008362>.
6. Wang S, Liu P, Wei J, Zhu Z, Shi Z, Shao D, et al. Tumor suppressor p53 protects mice against *Listeria monocytogenes* infection. *Sci Rep*. 2016;6:33815. <http://www.nature.com/articles/srep33815>.
7. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. *Nature*. 1995;378:203–6. <http://www.ncbi.nlm.nih.gov/pubmed/7477326>.
8. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. *Nature*. 1995;378:206–8. <http://www.ncbi.nlm.nih.gov/pubmed/7477327>.
9. Chavez-Reyes A, Parant JM, Amelse LL, de Oca Luna RM, Korsmeyer SJ, Lozano G. Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. *Cancer Res*. 2003;63:8664–9. <http://www.ncbi.nlm.nih.gov/pubmed/14695178>.
10. Tomovsky-Babeay S, Dadon D, Ziv O, Tzipilevich E, Kadosh T, Schyr-Ben Haroush R, et al. Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in  $\beta$  cells. *Cell Metab*. 2014;19:109–21. <https://linkinghub.elsevier.com/retrieve/pii/S1550413113004567>.
11. Pfaff MJ, Mukhopadhyay S, Hoofnagle M, Chabasse C, Sarkar R. Tumor suppressor protein p53 negatively regulates ischemia-induced angiogenesis and arteriogenesis. *J Vasc Surg*. 2018;68:2225–2335.e1. <https://linkinghub.elsevier.com/retrieve/pii/S0741521418310267>.
12. Hoshino A, Matoba S, Iwai-Kanai E, Nakamura H, Kimata M, Nakaoka M, et al. p53-TIGAR axis attenuates mitophagy to exacerbate cardiac damage after ischemia. *J Mol Cell Cardiol*. 2012;52:175–84. <http://www.ncbi.nlm.nih.gov/pubmed/22044588>.
13. Vaseva AV, Marchenko ND, Ji K, Tsrira SE, Holzmann S, Moll UM. p53 Opens the mitochondrial permeability transition pore to trigger necrosis. *Cell*. 2012;149:1536–48. <https://linkinghub.elsevier.com/retrieve/pii/S0092867412005934>.
14. The Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. *Cell*. 2017;169:1327–1341.e23. <https://linkinghub.elsevier.com/retrieve/pii/S0092867417306396>.
15. Katz S, Lechel A, Obenauf AC, Begus-Nahrmann Y, Kraus JM, Hoffmann EM, et al. Disruption of Trp53 in livers of mice induces formation of carcinomas with bilineal differentiation. *Gastroenterology*. 2012;142:1229–1239.e3. <https://linkinghub.elsevier.com/retrieve/pii/S0016508512002041>.
16. Michalopoulos GK. Liver regeneration. *J Cell Physiol*. 2007;213:286–300. <http://doi.wiley.com/10.1002/jcp.21172>.
17. Kurinna S, Stratton SA, Coban Z, Schumacher JM, Grompe M, Duncan AW, et al. p53 regulates a mitotic transcription program and determines ploidy in normal mouse liver. *Hepatology*. 2013;57:2004–13. <http://doi.wiley.com/10.1002/hep.26233>.
18. Huo Y, Yin S, Yan M, Win S, Aung Than T, Aghajan M, et al. Protective role of p53 in acetaminophen hepatotoxicity. *Free Radic Biol Med*. 2017;106:111–7. <https://linkinghub.elsevier.com/retrieve/pii/S0891584917300898>.
19. Borude P, Bhushan B, Gunewardena S, Akakpo J, Jaeschke H, Apte U. Pleiotropic role of p53 in injury and liver regeneration after acetaminophen overdose. *Am J Pathol*. 2018;188:1406–18. <https://doi.org/10.1016/j.ajpath.2018.03.006>.
20. Bellamy COC, Clarke AR, Wyllie AH, Harrison DJ. p53 deficiency in liver reduces local control of survival and proliferation, but does not affect apoptosis after DNA damage. *FASEB J*. 1997;11:591–9. <https://onlinelibrary.wiley.com/doi/abs/10.1096/fasebj.11.7.9212083>.
21. Buitrago-Molina LE, Marhenke S, Longeric T, Sharma AD, Boukouris AE, Geffers R, et al. The degree of liver injury determines the role of p21 in liver regeneration and hepatocarcinogenesis in mice. *Hepatology*. 2013;58:1143–52. <http://doi.wiley.com/10.1002/hep.26412>.
22. Marhenke S, Buitrago-Molina LE, Endig J, Orlik J, Schweitzer N, Klett S, et al. p21 promotes sustained liver regeneration and hepatocarcinogenesis in chronic cholestatic liver injury. *Gut*. 2014;63:1501–12. <http://gut.bmj.com/lookup/doi/10.1136/gutjnl-2013-304829>.
23. Bird TG, Müller M, Boulter L, Vincent DF, Ridgway RA, Lopez-Guadamillas E, et al. TGF $\beta$  inhibition restores a regenerative response in acute liver injury by suppressing paracrine senescence. *Sci Transl Med*. 2018;10:eaan1230. <https://stm.sciencemag.org/lookup/doi/10.1126/scitranslmed.aan1230>.
24. Lu W-Y, Bird TG, Boulter L, Tsuchiya A, Cole AM, Hay T, et al. Hepatic progenitor cells of biliary origin with liver repopulation capacity. *Nat Cell Biol*. 2015;17:971–83. <http://www.nature.com/articles/ncb3203>.
25. Farrell GC, Larter CZ, Hou JY, Zhang RH, Yeh MM, Williams J, et al. Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression. *J Gastroenterol Hepatol*. 2009;24:443–52. <http://doi.wiley.com/10.1111/j.1440-1746.2009.05785.x>.
26. Ferreira DMS, Afonso MB, Rodrigues PM, Simao AL, Pereira DM, Borralho PM, et al. c-Jun N-terminal kinase 1/c-Jun activation of the p53/MicroRNA 34a/Sirtuin 1 pathway contributes to apoptosis induced by deoxycholic acid in rat liver. *Mol Cell Biol*. 2014;34:1100–20. <http://mcb.asm.org/cgi/doi/10.1128/MCB.00420-13>.
27. Tian X-F, Ji F-J, Zang H-L, Cao H. Activation of the miR-34a/SIRT1/p53 signaling pathway contributes to the progress of liver fibrosis via inducing apoptosis in hepatocytes but not in HSCs. *PLoS ONE*. 2016;11:e0158657. <https://dx.plos.org/10.1371/journal.pone.0158657>.
28. Tao Y, Wang M, Chen E, Tang H. Liver regeneration: analysis of the main relevant signaling molecules. *Mediators Inflamm*. 2017;2017.
29. Shteyer E, Liao Y, Muglia LJ, Hruz PW, Rudnick DA. Disruption of hepatic adipogenesis is associated with impaired liver regeneration in mice. *Hepatology*. 2004;40:1322–32. <http://doi.wiley.com/10.1002/hep.20462>.
30. Newberry EP, Kennedy SM, Xie Y, Luo J, Stanley SE, Semenkovich CF, et al. Altered hepatic triglyceride content after partial hepatectomy without impaired liver regeneration in multiple murine genetic models. *Hepatology*. 2008;48:1097–105. <http://doi.wiley.com/10.1002/hep.22473>.
31. Weber LWD, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. *Crit Rev Toxicol*. 2003;33:105–36. <http://www.tandfonline.com/doi/full/10.1080/713611034>.
32. Boll M, Weber LWD, Becker E, Stampfl A. Mechanism of carbon tetrachloride-induced hepatotoxicity. Hepatocellular damage by reactive carbon tetrachloride metabolites. *Z fur Naturforsch - Sect C J Biosci*. 2001;56:649–59.
33. Long J, Wang X, Gao H, Liu Z, Liu C, Miao M, et al. Malonaldehyde acts as a mitochondrial toxin: Inhibitory effects on respiratory function and enzyme activities in isolated rat liver mitochondria. *Life Sci*. 2006;79:1466–72. <https://linkinghub.elsevier.com/retrieve/pii/S0024320506003377>.
34. Chen Z, Tian R, She Z, Cai J, Li H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. *Free Radic Biol Med*. 2020;152:116–41. <https://linkinghub.elsevier.com/retrieve/pii/S0891584919315151>.
35. Pessayre D. Role of mitochondria in non-alcoholic fatty liver disease. *J Gastroenterol Hepatol*. 2007;22:S20–7. <http://doi.wiley.com/10.1111/j.1440-1746.2006.04640.x>.
36. Eriksson SE, Ceder S, Bykov VJN, Wiman KG. p53 as a hub in cellular redox regulation and therapeutic target in cancer. *J Mol Cell Biol*. 2019;11:330–41. <https://academic.oup.com/jmcb/article/11/4/330/5320090>.
37. Lauterburg BH, Corcoran GB, Mitchell JR. Mechanism of action of N-acetylcysteine in the protection against the hepatotoxicity of acetaminophen in Rats in vivo. *J Clin Investig*. 1983;71:980–91. <http://www.jci.org/articles/view/110853>.
38. Okamoto K, Beach D. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. *EMBO J*. 1994;13:4816–22. <http://www.ncbi.nlm.nih.gov/pubmed/7957050>.
39. Vilborg A, Bersani C, Wilhelm MT, Wiman KG. The p53 target Wig-1: a regulator of mRNA stability and stem cell fate? *Cell Death Differ*. 2011;18:1434–40. <http://www.nature.com/articles/cdd201120>.
40. Brosh R, Sarig R, Natan EB, Molchadsky A, Madar S, Bornstein C, et al. p53-dependent transcriptional regulation of EDA2R and its involvement in chemotherapy-induced hair loss. *FEBS Lett*. 2010;584:2473–7. <http://doi.wiley.com/10.1016/j.febslet.2010.04.058>.
41. Thottassery JV, Zambetti GP, Arimori K, Schuetz EG, Schuetz JD. p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. *Proc Natl Acad Sci*. 1997;94:11037–42. <http://www.pnas.org/cgi/doi/10.1073/pnas.94.20.11037>.
42. Leung TM, Lu Y. Alcoholic liver disease: from CYP2E1 to CYP2A5. *Curr Mol Pharmacol*. 2017;10:172–8. <http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1874-4672&volume=10&issue=3&page=172>.
43. Lu Y, Zhang XH, Cederbaum AI. Ethanol induction of CYP2A5: Role of CYP2E1-ROS-Nrf2 pathway. *Toxicol Sci*. 2012;128:427–38. <https://academic.oup.com/toxsci/article/1649628/Ethanol>.
44. Su T, Ding X. Regulation of the cytochrome P450 2A genes. *Toxicol Appl Pharmacol*. 2004;199:285–94. <https://linkinghub.elsevier.com/retrieve/pii/S0041008X04000626>.
45. Hu H, Yu T, Arpiainen S, Lang MA, Hakkola J, Abu-Bakar A. Tumour suppressor protein p53 regulates the stress activated bilirubin oxidase cytochrome P450 2A6. *Toxicol Appl Pharmacol*. 2015;289:30–9. <https://doi.org/10.1016/j.taap.2015.08.021>.
46. Kim J, Yu L, Chen W, Xu Y, Wu M, Todorova D, et al. Wild-Type p53 promotes cancer metabolic switch by inducing PUMA-dependent suppression of oxidative phosphorylation. *Cancer Cell*. 2019;35:191–203.e8. <https://doi.org/10.1016/j.ccell.2018.12.012>.
47. Grier JD, Yan W, Lozano G. Conditional allele of mdm2 which encodes a p53 inhibitor. *genesis*. 2002;32:145–7. <https://onlinelibrary.wiley.com/doi/10.1002/gene.10066>.
48. Yanger K, Knigin D, Zong Y, Maggs L, Gu G, Akiyama H, et al. Adult hepatocytes are generated by self-duplication rather than stem cell differentiation. *Cell Stem Cell*. 2014 Sep;15:340–9. <https://linkinghub.elsevier.com/retrieve/pii/S1934590914002513>.

49. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. *Science*. 2004;303:844–8. <http://www.ncbi.nlm.nih.gov/pubmed/14704432>.
50. Vroegop SM, Decker DE, Buxser SE. Localization of damage induced by reactive oxygen species in cultured cells. *Free Radic Biol Med*. 1995;18:141–51. <https://linkinghub.elsevier.com/retrieve/pii/S089158499400107U>.
51. Rudraiah S, Gu X, Hines RN, Manautou JE. Oxidative stress-responsive transcription factor NRF2 is not indispensable for the human hepatic Flavin-containing monooxygenase-3 (FMO3) gene expression in HepG2 cells. *Toxicol Vitro*. 2016;31:54–9. <https://linkinghub.elsevier.com/retrieve/pii/S0887233315300175>.
52. Flier JS, Underhill LH, Dvorak HF. Tumors: wounds that do not heal. *N Engl J Med*. 1986;315:1650–9. <http://www.nejm.org/doi/abs/10.1056/NEJM198612253152606>.
53. Scholten D, Trebicka J, Liedtke C, Weiskirchen R. The carbon tetrachloride model in mice. *Lab Anim*. 2015;49:4–11. <http://journals.sagepub.com/doi/10.1177/0023677215571192>.
54. Batailler R, Brenner DA. Liver fibrosis. *J Clin Investig*. 2005;115:209–18. <http://www.jci.org/articles/view/24282>.
55. Cichoż-Lach H, Michalak A. Oxidative stress as a crucial factor in liver diseases. *World J Gastroenterol*. 2014;20:8082. <http://www.wjgnet.com/1007-9327/full/v20/i25/8082.htm>.
56. Richter K, Kietzmann T. Reactive oxygen species and fibrosis: further evidence of a significant liaison. *Cell Tissue Res*. 2016;365:591–605. <http://link.springer.com/10.1007/s00441-016-2445-3>.
57. Miyaoka Y, Ebato K, Kato H, Arakawa S, Shimizu S, Miyajima A. Hypertrophy and unconventional cell division of hepatocytes underlie liver regeneration. *Curr Biol*. 2012;22:1166–75. <https://doi.org/10.1016/j.cub.2012.05.016>.
58. Heindryckx F, Colle I, Van Vlierberghhe H. Experimental mouse models for hepatocellular carcinoma research. *Int J Exp Pathol*. 2009;90:367–86. <http://doi.wiley.com/10.1111/j.1365-2613.2009.00656.x>.
59. Erickson BJ, Kirk S, Lee Y, Bathe O, Kearns M, Gerdes C, et al. Radiology data from the cancer genome atlas liver hepatocellular carcinoma [TCGA-LIHC] collection. The Cancer Imaging Archive; 2016.
60. Ratajczak MZ, Bujko K, Mack A, Kucia M, Ratajczak J. Cancer from the perspective of stem cells and misappropriated tissue regeneration mechanisms. *Leukemia*. 2018;32:2519–26. <http://www.nature.com/articles/s41375-018-0294-7>.
61. Zhou X, Zhuo X, Xie F, Kluetzman K, Shu Y-Z, Humphreys WG, et al. Role of CYP2A5 in the clearance of nicotine and cotinine: insights from studies on a Cyp2a5-null mouse model. *J Pharmacol Exp Ther*. 2010;332:578–87. <http://jpet.aspetjournals.org/lookup/doi/10.1124/jpet.109.162610>.
62. Hong F, Si C, Gao P, Cederbaum AI, Xiong H, Lu Y. The role of CYP2A5 in liver injury and fibrosis: chemical-specific difference. *Naunyn Schmiedebergs Arch Pharmacol*. 2016;389:33–43. <http://link.springer.com/10.1007/s00210-015-1172-8>.
63. Tajan M, Hock AKAK, Blagih J, Robertson NANA, Labuschagne CFCF, Kruijswijk F, et al. A role for p53 in the adaptation to glutamine starvation through the expression of SLC1A3. *Cell Metab*. 2018;28:721–36.
64. Maddocks ODK, Berkers CR, Mason SM, Zheng L, Blyth K, Gottlieb E, et al. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. *Nature*. 2013;493:542–6. <http://www.ncbi.nlm.nih.gov/pubmed/23242140>.
65. Tarangelo A, Magtanong L, Biegging-Rolett KT, Li Y, Ye J, Attardi LD, et al. p53 suppresses metabolic stress-induced ferroptosis in cancer cells. *Cell Rep*. 2018;22:569–75. <https://linkinghub.elsevier.com/retrieve/pii/S2211124717319149>.
66. Xie Y, Zhu S, Song X, Sun X, Fan Y, Liu J, et al. The tumor suppressor p53 limits ferroptosis by blocking DPP4 activity. *Cell Rep*. 2017;20:1692–704. <http://www.ncbi.nlm.nih.gov/pubmed/28813679>.
67. Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S, et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. *Proc Natl Acad Sci USA*. 2010;107:7461–6.
68. Bensaad K, Tsuruta A, Selak MA, Vidal MNC, Nakano K, Barrons R, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. *Cell*. 2006;126:107–20. <http://www.ncbi.nlm.nih.gov/pubmed/16839880>.
69. Humpton TJ, Hock AK, Maddocks ODK, Vousden KH. p53-mediated adaptation to serine starvation is retained by a common tumour-derived mutant. *Cancer Metab*. 2018;6:18. <http://www.ncbi.nlm.nih.gov/pubmed/30524726>.
70. Tran TQ, Lowman XH, Reid MA, Pan M, Yang Y, Kong M. Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction. 2016;36:1991–2001. <https://doi.org/10.1038/ncr.2016.360>.
71. Kemp CJ, Donehower LA, Bradley A, Balmain A. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. *Cell*. 1993;74:813–22. <https://linkinghub.elsevier.com/retrieve/pii/S009286749390461X>.
72. Greenhalgh DA, Wang XJ, Donehower LA, Roop DR. Paradoxical tumor inhibitory effect of p53 loss in transgenic mice expressing epidermal-targeted v-rasHa, v-fos, or human transforming growth factor alpha. *Cancer Res*. 1996;56:4413–23. <http://www.ncbi.nlm.nih.gov/pubmed/8813135>.
73. Kelly-Spratt KS, Gurley KE, Yasui Y, Kemp CJ. p19 Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways. *PLoS Biol*. 2004;2:e242. <https://dx.plos.org/10.1371/journal.pbio.0020242>.
74. Kadlubar S, Anderson JP, Sweeney C, Gross MD, Lang NP, Kadlubar FF, et al. Phenotypic CYP2A6 variation and the risk of pancreatic cancer. *JOP*. 2009;10:263–70. <http://www.ncbi.nlm.nih.gov/pubmed/19454817>.
75. Nowell S, Sweeney C, Hammons G, Kadlubar FF, Lang NP. CYP2A6 activity determined by caffeine phenotyping: association with colorectal cancer risk. *Cancer Epidemiol Biomarkers Prev*. 2002;11:377–83. <http://www.ncbi.nlm.nih.gov/pubmed/11927498>.
76. Ariyoshi N, Miyamoto M, Umetsu Y, Kunitoh H, Dosaka-Akita H, Sawamura Y-I, et al. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. *Cancer Epidemiol Biomarkers Prev*. 2002;11:890–4. <http://www.ncbi.nlm.nih.gov/pubmed/12223434>.
77. Tan W, Chen GF, Xing DY, Song CY, Kadlubar FF, Lin DX. Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. *Int J Cancer*. 2001;95:96–101. <http://www.ncbi.nlm.nih.gov/pubmed/11241319>.
78. Wang H, Tan W, Hao B, Miao X, Zhou G, He F, et al. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. *Cancer Res*. 2003;63:8057–61. <http://www.ncbi.nlm.nih.gov/pubmed/14633739>.
79. Kennedy OJ, Roderick P, Buchanan R, Fallowfield JA, Hayes PC, Parkes J. Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysis. *BMJ Open*. 2017;7:e013739. <https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2016-013739>.
80. Dhar D, Antonucci L, Nakagawa H, Kim JY, Glitzner E, Caruso S, et al. Liver cancer initiation requires p53 inhibition by CD44-enhanced growth factor signaling. *Cancer Cell*. 2018 Jun;33:1061–1077.e6. <https://linkinghub.elsevier.com/retrieve/pii/S1535610818302174>.
81. Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, Moates JM, et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic  $\beta$  cell-specific gene knock-outs using cre recombinase. *J Biol Chem*. 1999;274:305–15. <http://www.jbc.org/lookup/doi/10.1074/jbc.274.1.305>.
82. Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. *Genes Dev*. 2000;14:994–1004. <http://www.ncbi.nlm.nih.gov/pubmed/10783170>.
83. Zhu R, Zeng G, Chen Y, Zhang Q, Liu B, Liu J, et al. Oroxylin A accelerates liver regeneration in CCl4-induced acute liver injury mice. *PLoS ONE*. 2013;8:e71612. <https://dx.plos.org/10.1371/journal.pone.0071612>.
84. Luche H, Weber O, Nageswara Rao T, Blum C, Fehling HJ. Faithful activation of an extra-bright red fluorescent protein in “knock-in” Cre-reporter mice ideally suited for lineage tracing studies. *Eur J Immunol*. 2007;37:43–53. <http://www.ncbi.nlm.nih.gov/pubmed/17171761>.
85. Humpton TJ, Nomura K, Weber J, Magnussen HM, Hock AK, Nixon C, et al. Differential requirements for MDM2 E3 activity during embryogenesis and in adult mice. *Genes Dev*. 2021;35:117–32. <http://genesdev.cshlp.org/lookup/doi/10.1101/gad.341875.120>.
86. Jonkers J, Meuwissen R, Van der Gulden H, Peterse H, Van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. *Nat Genet*. 2001;29:418–25.
87. Fisher S, Barry A, Abreu J, Minie B, Nolan J, Delorey TM, et al. A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. *Genome Biol*. 2011;12:R1. <http://genomebiology.biomedcentral.com/articles/10.1186/gb-2011-12-1-r1>.
88. Andrews S. FastQC: a quality control tool for high throughput sequence data. 2018. <http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc>.
89. Wingett S. FastQ Screen. 2018. [http://www.bioinformatics.babraham.ac.uk/projects/fastq\\_screen/](http://www.bioinformatics.babraham.ac.uk/projects/fastq_screen/).
90. Zerbino DR, Achuthan P, Akanni W, Amode MR, Barrell D, Bhai J, et al. Ensembl 2018. *Nucleic Acids Res*. 2018 46:D754–61. <http://academic.oup.com/nar/article/46/D1/D754/4634002>.
91. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. *Bioinformatics*. 2009;25:1105–11. <https://academic.oup.com/bioinformatics/article-lookup/doi/10.1093/bioinformatics/btp120>.
92. Anders S, Pyl PT, Huber W. HTSeq—a Python framework to work with high-throughput sequencing data. *Bioinformatics*. 2015;31:166–9. <https://academic.oup.com/bioinformatics/article-lookup/doi/10.1093/bioinformatics/btu638>.
93. R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2018. <https://www.r-project.org/>.

94. Huber W, Carey VJ, Gentleman R, Anders S, Carlson M, Carvalho BS, et al. Orchestrating high-throughput genomic analysis with Bioconductor. *Nat Methods*. 2015;12:115–21. <http://www.nature.com/articles/nmeth.3252>.
95. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol*. 2014;15:550. <http://genomebiology.biomedcentral.com/articles/10.1186/s13059-014-0550-8>.
96. Warnes GR, Bolker B, Bonebakker L, Gentleman R, Huber W, Liaw A, et al. gplots: various R programming tools for plotting data. R package version 3.1.0. 2020. <https://cran.r-project.org/package=gplots>.
97. Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. *Bioinformatics*. 2018;34:i884–90. <https://academic.oup.com/bioinformatics/article/34/17/i884/5093234>.
98. Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. *Nat Methods*. 2015;12:357–60. <http://www.nature.com/articles/nmeth.3317>.
99. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio Cancer genomics portal: an open platform for exploring multidimensional cancer genomics data: Fig. 1. *Cancer Discov*. 2012;2:401–4. <http://cancerdiscovery.aacrjournals.org/lookup/doi/10.1158/2159-8290.CD-12-0095>.
100. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal*. 2013;6:pl1–pl1. <https://stke.sciencemag.org/lookup/doi/10.1126/scisignal.2004088>.
101. Kassambara A, Kosinski M, Biecek P. Drawing survival curves using 'ggplot2'. 2020. <http://www.sthda.com/english/rpkgs/survminer/>.
102. Wei T, Simko V. R package "corrplot": visualization of a correlation matrix. 2017. <https://github.com/taiyun/corrplot>.

## ACKNOWLEDGEMENTS

We would like to thank the Core Facilities and Advanced Technologies at the CRUK Beatson Institute, in particular the animal facilities staff, the histology team, the Molecular Technologies group, and the Bioinformatics services. We thank Catherine Winchester for comments on the manuscript.

## AUTHOR CONTRIBUTIONS

TJH and KHV conceived and designed the project. HH analysed the RNA-seq data and liver TCGA-LIHC data. CK performed experiments with *Mdm2*<sup>Ex5/6Δ</sup> mice, for which funding was provided by TGB. CN performed IHC. WC performed RNA sequencing. AH and RS analysed RNA-seq data. TJH performed all other experiments and data analysis with assistance from HH. The work was supervised by TGB, KB and KHV. TJH and KHV wrote the manuscript and all authors discussed the results and revised and approved the manuscript prior to submission.

## FUNDING

This work was funded by Cancer Research UK grant C596/A26855 and supported by The Francis Crick Institute which receives its core funding from Cancer Research UK (FC001557), the United Kingdom Medical Research Council (FC001557), and the Wellcome Trust (FC001557), and the CRUK Beatson Institute which receives its core funding from Cancer Research UK grant C596/A17196. HH was funded by BBSRC

grant BB/N017005/2. Additional funding for the work was provided by Cancer Research UK grant A29799 (KB). TGB was funded by the Wellcome Trust (Grant number: WT107492Z) and CRUK HUNTER Accelerator Award (Grant number: A26813).

## COMPETING INTERESTS

KHV is on the board of directors and a shareholder of Bristol Myers Squibb, and on the science advisory board (with stock options) of PMV Pharma, RAZE Therapeutics and Volastra Therapeutics, Inc. She is also on the SAB of Ludwig Cancer Research. KHV is a co-founder and consultant of Faeth Therapeutics. She has been in receipt of research funding from Astex Pharmaceuticals and AstraZeneca and contributed to CRUK Cancer Research Technology filing of Patent Application WO/2017/144877. TGB is in receipt of research funding from AstraZeneca.

## ETHICAL APPROVAL

Procedures involving mice were performed under Home Office licence numbers 70/8645, PP6345023, and 70/8891. Experiments were conducted in accordance with the Animals (Scientific Procedures) Act 1986 and the EU Directive 2010 and sanctioned by Local Ethical Review Process (University of Glasgow). No human samples were used in this study.

## ADDITIONAL INFORMATION

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41418-021-00871-3>.

**Correspondence** and requests for materials should be addressed to Timothy J. Humpton or Karen H. Vousden.

**Reprints and permission information** is available at <http://www.nature.com/reprints>

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021